|
TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer. |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Janssen |
|
|
|
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst) |
Travel, Accommodations, Expenses - Medivation/Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Astellas Pharma; Janssen; Novartis; Pfizer; Tolmar |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Sanofi; Tolmar |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Novartis |
Research Funding - Astellas Pharma |
Travel, Accommodations, Expenses - Astellas Pharma; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Eisai (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research. |